Back to News
Market Impact: 0.4
ZYUS Sees Opioid Reduction Signal With Trichomylin In Phase 2a
Source: Nasdaq
Healthcare & Biotech
ZYUS Life Sciences reported positive topline results from its Phase 2a UTOPIA-1 trial of Trichomylin softgel capsules for moderate-to-severe cancer-related pain in patients with advanced cancer. The clinical readout is a positive development for the company’s oncology pain-treatment pipeline, though the article did not provide efficacy or safety metrics.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
ZYUS0.78
More News
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Cullinan initiates FDA filing for lung cancer drug zipalertinib
- Moderna to replace Warner Bros Discovery on Nasdaq 100
- Why McKesson Stock Soared More Than 5% Higher Today
- This biotech making precision medicines for cancer could nearly triple, says JPMorgan
- The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning Squawk